Weak correlation between antibody titers and neutralizing activity in sera from SARS‐CoV‐2 infected subjects
Plenty of serologic tests for severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) have been developed so far, thus documenting the importance of evaluating the relevant features of the immune response to this viral agent. The performance of these assays is currently under investigation. Amo...
Saved in:
Published in | Journal of medical virology Vol. 93; no. 4; pp. 2160 - 2167 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Wiley Subscription Services, Inc
01.04.2021
John Wiley and Sons Inc |
Subjects | |
Online Access | Get full text |
ISSN | 0146-6615 1096-9071 1096-9071 |
DOI | 10.1002/jmv.26605 |
Cover
Loading…
Abstract | Plenty of serologic tests for severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) have been developed so far, thus documenting the importance of evaluating the relevant features of the immune response to this viral agent. The performance of these assays is currently under investigation. Amongst them, LIAISON® SARS‐CoV‐2 S1/S2 IgG by DiaSorin and Elecsys Anti‐SARS‐CoV‐2 cobas® by Roche are currently used by laboratory medicine hospital departments in Italy and many other countries. In the present study, we firstly compared two serologic tests on serum samples collected at two different time points from 46 laboratory‐confirmed coronavirus disease‐2019 (COVID‐19) subjects. Secondly, 85 negative serum samples collected before the SARS‐CoV‐2 pandemic were analyzed. Thirdly, possible correlations between antibody levels and the resulting neutralizing activity against a clinical isolate of SARS‐CoV‐2 were evaluated. Results revealed that both tests are endowed with low sensitivity on the day of hospital admission, which increased to 97.8% and 100% for samples collected after 15 days for DiaSorin and Roche tests, respectively. The specificity evaluated for the two tests ranges from 96.5% to 100%, respectively. Importantly, a poor direct correlation between antibody titers and neutralizing activity levels was evidenced in the present study. These data further shed light on both potentials and possible limitations related to SARS‐CoV‐2 serology. In this context, great efforts are still necessary for investigating antibody kinetics to develop novel diagnostic algorithms. Moreover, further investigations on the role of neutralizing antibodies and their correlate of protection will be of paramount importance for the development of effective vaccines.
Highlights
A comparative analysis between two serologic assays for the detection of antibodies directed against SARS‐CoV‐2 was carried out on sera from subjects testing positive for SARS‐CoV‐2 nasopharyngeal swabs.
Results revealed that both tests are endowed with low sensitivity on the day of hospital admission, which increased for samples collected after 15 days.
A poor direct correlation between antibody titers and neutralizing activity levels was evidenced in the present study. |
---|---|
AbstractList | Plenty of serologic tests for severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) have been developed so far, thus documenting the importance of evaluating the relevant features of the immune response to this viral agent. The performance of these assays is currently under investigation. Amongst them, LIAISON® SARS‐CoV‐2 S1/S2 IgG by DiaSorin and Elecsys Anti‐SARS‐CoV‐2 cobas® by Roche are currently used by laboratory medicine hospital departments in Italy and many other countries. In the present study, we firstly compared two serologic tests on serum samples collected at two different time points from 46 laboratory‐confirmed coronavirus disease‐2019 (COVID‐19) subjects. Secondly, 85 negative serum samples collected before the SARS‐CoV‐2 pandemic were analyzed. Thirdly, possible correlations between antibody levels and the resulting neutralizing activity against a clinical isolate of SARS‐CoV‐2 were evaluated. Results revealed that both tests are endowed with low sensitivity on the day of hospital admission, which increased to 97.8% and 100% for samples collected after 15 days for DiaSorin and Roche tests, respectively. The specificity evaluated for the two tests ranges from 96.5% to 100%, respectively. Importantly, a poor direct correlation between antibody titers and neutralizing activity levels was evidenced in the present study. These data further shed light on both potentials and possible limitations related to SARS‐CoV‐2 serology. In this context, great efforts are still necessary for investigating antibody kinetics to develop novel diagnostic algorithms. Moreover, further investigations on the role of neutralizing antibodies and their correlate of protection will be of paramount importance for the development of effective vaccines.
Highlights
A comparative analysis between two serologic assays for the detection of antibodies directed against SARS‐CoV‐2 was carried out on sera from subjects testing positive for SARS‐CoV‐2 nasopharyngeal swabs.
Results revealed that both tests are endowed with low sensitivity on the day of hospital admission, which increased for samples collected after 15 days.
A poor direct correlation between antibody titers and neutralizing activity levels was evidenced in the present study. Plenty of serologic tests for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed so far, thus documenting the importance of evaluating the relevant features of the immune response to this viral agent. The performance of these assays is currently under investigation. Amongst them, LIAISON® SARS-CoV-2 S1/S2 IgG by DiaSorin and Elecsys Anti-SARS-CoV-2 cobas® by Roche are currently used by laboratory medicine hospital departments in Italy and many other countries. In the present study, we firstly compared two serologic tests on serum samples collected at two different time points from 46 laboratory-confirmed coronavirus disease-2019 (COVID-19) subjects. Secondly, 85 negative serum samples collected before the SARS-CoV-2 pandemic were analyzed. Thirdly, possible correlations between antibody levels and the resulting neutralizing activity against a clinical isolate of SARS-CoV-2 were evaluated. Results revealed that both tests are endowed with low sensitivity on the day of hospital admission, which increased to 97.8% and 100% for samples collected after 15 days for DiaSorin and Roche tests, respectively. The specificity evaluated for the two tests ranges from 96.5% to 100%, respectively. Importantly, a poor direct correlation between antibody titers and neutralizing activity levels was evidenced in the present study. These data further shed light on both potentials and possible limitations related to SARS-CoV-2 serology. In this context, great efforts are still necessary for investigating antibody kinetics to develop novel diagnostic algorithms. Moreover, further investigations on the role of neutralizing antibodies and their correlate of protection will be of paramount importance for the development of effective vaccines. Plenty of serologic tests for severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) have been developed so far, thus documenting the importance of evaluating the relevant features of the immune response to this viral agent. The performance of these assays is currently under investigation. Amongst them, LIAISON® SARS‐CoV‐2 S1/S2 IgG by DiaSorin and Elecsys Anti‐SARS‐CoV‐2 cobas® by Roche are currently used by laboratory medicine hospital departments in Italy and many other countries. In the present study, we firstly compared two serologic tests on serum samples collected at two different time points from 46 laboratory‐confirmed coronavirus disease‐2019 (COVID‐19) subjects. Secondly, 85 negative serum samples collected before the SARS‐CoV‐2 pandemic were analyzed. Thirdly, possible correlations between antibody levels and the resulting neutralizing activity against a clinical isolate of SARS‐CoV‐2 were evaluated. Results revealed that both tests are endowed with low sensitivity on the day of hospital admission, which increased to 97.8% and 100% for samples collected after 15 days for DiaSorin and Roche tests, respectively. The specificity evaluated for the two tests ranges from 96.5% to 100%, respectively. Importantly, a poor direct correlation between antibody titers and neutralizing activity levels was evidenced in the present study. These data further shed light on both potentials and possible limitations related to SARS‐CoV‐2 serology. In this context, great efforts are still necessary for investigating antibody kinetics to develop novel diagnostic algorithms. Moreover, further investigations on the role of neutralizing antibodies and their correlate of protection will be of paramount importance for the development of effective vaccines. Plenty of serologic tests for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed so far, thus documenting the importance of evaluating the relevant features of the immune response to this viral agent. The performance of these assays is currently under investigation. Amongst them, LIAISON® SARS-CoV-2 S1/S2 IgG by DiaSorin and Elecsys Anti-SARS-CoV-2 cobas® by Roche are currently used by laboratory medicine hospital departments in Italy and many other countries. In the present study, we firstly compared two serologic tests on serum samples collected at two different time points from 46 laboratory-confirmed coronavirus disease-2019 (COVID-19) subjects. Secondly, 85 negative serum samples collected before the SARS-CoV-2 pandemic were analyzed. Thirdly, possible correlations between antibody levels and the resulting neutralizing activity against a clinical isolate of SARS-CoV-2 were evaluated. Results revealed that both tests are endowed with low sensitivity on the day of hospital admission, which increased to 97.8% and 100% for samples collected after 15 days for DiaSorin and Roche tests, respectively. The specificity evaluated for the two tests ranges from 96.5% to 100%, respectively. Importantly, a poor direct correlation between antibody titers and neutralizing activity levels was evidenced in the present study. These data further shed light on both potentials and possible limitations related to SARS-CoV-2 serology. In this context, great efforts are still necessary for investigating antibody kinetics to develop novel diagnostic algorithms. Moreover, further investigations on the role of neutralizing antibodies and their correlate of protection will be of paramount importance for the development of effective vaccines.Plenty of serologic tests for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed so far, thus documenting the importance of evaluating the relevant features of the immune response to this viral agent. The performance of these assays is currently under investigation. Amongst them, LIAISON® SARS-CoV-2 S1/S2 IgG by DiaSorin and Elecsys Anti-SARS-CoV-2 cobas® by Roche are currently used by laboratory medicine hospital departments in Italy and many other countries. In the present study, we firstly compared two serologic tests on serum samples collected at two different time points from 46 laboratory-confirmed coronavirus disease-2019 (COVID-19) subjects. Secondly, 85 negative serum samples collected before the SARS-CoV-2 pandemic were analyzed. Thirdly, possible correlations between antibody levels and the resulting neutralizing activity against a clinical isolate of SARS-CoV-2 were evaluated. Results revealed that both tests are endowed with low sensitivity on the day of hospital admission, which increased to 97.8% and 100% for samples collected after 15 days for DiaSorin and Roche tests, respectively. The specificity evaluated for the two tests ranges from 96.5% to 100%, respectively. Importantly, a poor direct correlation between antibody titers and neutralizing activity levels was evidenced in the present study. These data further shed light on both potentials and possible limitations related to SARS-CoV-2 serology. In this context, great efforts are still necessary for investigating antibody kinetics to develop novel diagnostic algorithms. Moreover, further investigations on the role of neutralizing antibodies and their correlate of protection will be of paramount importance for the development of effective vaccines. Plenty of serologic tests for severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) have been developed so far, thus documenting the importance of evaluating the relevant features of the immune response to this viral agent. The performance of these assays is currently under investigation. Amongst them, LIAISON® SARS‐CoV‐2 S1/S2 IgG by DiaSorin and Elecsys Anti‐SARS‐CoV‐2 cobas® by Roche are currently used by laboratory medicine hospital departments in Italy and many other countries. In the present study, we firstly compared two serologic tests on serum samples collected at two different time points from 46 laboratory‐confirmed coronavirus disease‐2019 (COVID‐19) subjects. Secondly, 85 negative serum samples collected before the SARS‐CoV‐2 pandemic were analyzed. Thirdly, possible correlations between antibody levels and the resulting neutralizing activity against a clinical isolate of SARS‐CoV‐2 were evaluated. Results revealed that both tests are endowed with low sensitivity on the day of hospital admission, which increased to 97.8% and 100% for samples collected after 15 days for DiaSorin and Roche tests, respectively. The specificity evaluated for the two tests ranges from 96.5% to 100%, respectively. Importantly, a poor direct correlation between antibody titers and neutralizing activity levels was evidenced in the present study. These data further shed light on both potentials and possible limitations related to SARS‐CoV‐2 serology. In this context, great efforts are still necessary for investigating antibody kinetics to develop novel diagnostic algorithms. Moreover, further investigations on the role of neutralizing antibodies and their correlate of protection will be of paramount importance for the development of effective vaccines. A comparative analysis between two serologic assays for the detection of antibodies directed against SARS‐CoV‐2 was carried out on sera from subjects testing positive for SARS‐CoV‐2 nasopharyngeal swabs. Results revealed that both tests are endowed with low sensitivity on the day of hospital admission, which increased for samples collected after 15 days. A poor direct correlation between antibody titers and neutralizing activity levels was evidenced in the present study. |
Author | Criscuolo, Elena Diotti, Roberta A. Locatelli, Massimo Rolla, Serena Strollo, Marta Clementi, Nicola Mancini, Nicasio Clementi, Massimo Ambrosi, Alessandro Burioni, Roberto |
AuthorAffiliation | 4 Laboratory of Medical Microbiology and Virology IRCCS San Raffaele Hospital Milan Italy 3 Faculty of Medicine and Surgery Vita‐Salute San Raffaele University Milan Italy 2 Laboratory Medicine Service IRCCS San Raffaele Hospital Milan Italy 1 Laboratory of Medical Microbiology and Virology Vita‐Salute San Raffaele University Milan Italy |
AuthorAffiliation_xml | – name: 4 Laboratory of Medical Microbiology and Virology IRCCS San Raffaele Hospital Milan Italy – name: 2 Laboratory Medicine Service IRCCS San Raffaele Hospital Milan Italy – name: 3 Faculty of Medicine and Surgery Vita‐Salute San Raffaele University Milan Italy – name: 1 Laboratory of Medical Microbiology and Virology Vita‐Salute San Raffaele University Milan Italy |
Author_xml | – sequence: 1 givenname: Elena orcidid: 0000-0003-0185-3147 surname: Criscuolo fullname: Criscuolo, Elena organization: Vita‐Salute San Raffaele University – sequence: 2 givenname: Roberta A. surname: Diotti fullname: Diotti, Roberta A. organization: Vita‐Salute San Raffaele University – sequence: 3 givenname: Marta surname: Strollo fullname: Strollo, Marta organization: IRCCS San Raffaele Hospital – sequence: 4 givenname: Serena surname: Rolla fullname: Rolla, Serena organization: IRCCS San Raffaele Hospital – sequence: 5 givenname: Alessandro orcidid: 0000-0003-1976-5663 surname: Ambrosi fullname: Ambrosi, Alessandro organization: Vita‐Salute San Raffaele University – sequence: 6 givenname: Massimo surname: Locatelli fullname: Locatelli, Massimo organization: IRCCS San Raffaele Hospital – sequence: 7 givenname: Roberto surname: Burioni fullname: Burioni, Roberto organization: Vita‐Salute San Raffaele University – sequence: 8 givenname: Nicasio surname: Mancini fullname: Mancini, Nicasio organization: IRCCS San Raffaele Hospital – sequence: 9 givenname: Massimo surname: Clementi fullname: Clementi, Massimo organization: IRCCS San Raffaele Hospital – sequence: 10 givenname: Nicola orcidid: 0000-0002-1822-9861 surname: Clementi fullname: Clementi, Nicola email: clementi.nicola@hsr.it organization: IRCCS San Raffaele Hospital |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33064340$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kc1u1DAUhS1URKeFBS-ALLGhi7T-iZ1kg1SNoICKkCiUpeU4N8VDYg-2M9Ww4hF4Rp4ET2eKoIKNf3S_c3ysc4D2nHeA0GNKjikh7GQxro6ZlETcQzNKGlk0pKJ7aEZoKQspqdhHBzEuCCF1w9gDtM85kSUvyQwtP4H-go0PAQadrHe4hXQN4LB2yba-W-NkE4SY7x12MKWgB_vNuiusTbIrm9bYOhwhaNwHP-KL0_cXP7__mPvLvLI868Ek6HCc2kU-xYfofq-HCI92-yH6-PLFh_mr4vzd2ev56XlhBK9E0dGadXUNpqVSSNELwfu-pYzJWpDOlGXdCwN91ZDakJrSpuK6qTRpCMhOg-CH6PnWdzm1I3QG3Ca5WgY76rBWXlv198TZz-rKr1QlK1EJng2e7QyC_zpBTGq00cAwaAd-ioqVgtai4WTz1tM76MJPweXvZaohlNVcyEw9-TPR7yi3ZWTgZAuY4GMM0Ctj000pOaAdFCVqU7fKdauburPi6I7i1vRf7M792g6w_j-o3ry93Cp-AfIovGs |
CitedBy_id | crossref_primary_10_3390_ani12111459 crossref_primary_10_3390_vaccines10050801 crossref_primary_10_1136_annrheumdis_2021_220647 crossref_primary_10_1136_annrheumdis_2021_221735 crossref_primary_10_3346_jkms_2022_37_e135 crossref_primary_10_1136_ard_2022_222550 crossref_primary_10_1016_j_heliyon_2024_e24513 crossref_primary_10_1038_s41598_021_91746_7 crossref_primary_10_3390_vaccines9111357 crossref_primary_10_3390_diagnostics12010085 crossref_primary_10_3390_vaccines10071044 crossref_primary_10_1097_MD_0000000000029362 crossref_primary_10_1177_23742895211002802 crossref_primary_10_3390_vaccines11030598 crossref_primary_10_1016_j_vaccine_2022_03_001 crossref_primary_10_3390_ani13223498 crossref_primary_10_1111_trf_16693 crossref_primary_10_3390_v14010061 crossref_primary_10_3390_v14061232 crossref_primary_10_3390_life12122064 crossref_primary_10_1111_trf_17083 crossref_primary_10_1136_annrheumdis_2021_221916 crossref_primary_10_3390_vaccines11081380 crossref_primary_10_3389_fimmu_2024_1323406 crossref_primary_10_3389_fimmu_2022_833085 crossref_primary_10_1093_rheumatology_keac103 crossref_primary_10_1016_j_vaccine_2024_07_026 crossref_primary_10_3346_jkms_2021_36_e158 crossref_primary_10_1128_spectrum_01315_22 crossref_primary_10_1056_NEJMoa2109072 crossref_primary_10_3390_vaccines11020476 crossref_primary_10_1111_apa_16031 crossref_primary_10_4049_jimmunol_2200487 crossref_primary_10_3390_vaccines10060901 crossref_primary_10_1016_j_clim_2022_108961 crossref_primary_10_3390_vaccines11040819 crossref_primary_10_3390_life14070791 crossref_primary_10_3390_ijms25105509 crossref_primary_10_3390_vaccines9070714 crossref_primary_10_3390_jpm11121253 crossref_primary_10_3390_vaccines10020260 crossref_primary_10_3390_covid4080091 |
Cites_doi | 10.15557/PiMR.2020.0024 10.1101/2020.03.18.20038018 10.1038/s41420-020-0275-2 10.2307/2531595 10.1101/2020.03.30.20047365 10.1101/2020.07.09.20148429 10.1016/j.immuni.2020.03.007 10.1038/s41541-020-0198-1 10.1128/JCM.00461-20 10.3389/fmolb.2020.00157 10.1002/(SICI)1097-0258(19971015)16:19<2143::AID-SIM655>3.0.CO;2-3 10.1101/2020.07.21.20159178 10.1007/s11427-020-1805-0 10.1016/S1473-3099(20)30196-1 10.1128/JCM.01224-20 |
ContentType | Journal Article |
Copyright | 2020 Wiley Periodicals LLC 2020 Wiley Periodicals LLC. 2021 Wiley Periodicals LLC |
Copyright_xml | – notice: 2020 Wiley Periodicals LLC – notice: 2020 Wiley Periodicals LLC. – notice: 2021 Wiley Periodicals LLC |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QL 7TK 7U9 8FD C1K FR3 H94 K9. M7N P64 RC3 7X8 5PM |
DOI | 10.1002/jmv.26605 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Bacteriology Abstracts (Microbiology B) Neurosciences Abstracts Virology and AIDS Abstracts Technology Research Database Environmental Sciences and Pollution Management Engineering Research Database AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Algology Mycology and Protozoology Abstracts (Microbiology C) Biotechnology and BioEngineering Abstracts Genetics Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Genetics Abstracts Virology and AIDS Abstracts Technology Research Database Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Engineering Research Database Neurosciences Abstracts Biotechnology and BioEngineering Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
DatabaseTitleList | MEDLINE Genetics Abstracts MEDLINE - Academic CrossRef |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
DocumentTitleAlternate | CRISCUOLO et al |
EISSN | 1096-9071 |
EndPage | 2167 |
ExternalDocumentID | PMC7675753 33064340 10_1002_jmv_26605 JMV26605 |
Genre | article Journal Article |
GeographicLocations | Italy |
GeographicLocations_xml | – name: Italy |
GroupedDBID | --- .3N .55 .GA .GJ .Y3 05W 0R~ 10A 1L6 1OB 1OC 1ZS 31~ 33P 3O- 3SF 3WU 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5RE 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANHP AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABEML ABIJN ABJNI ABOCM ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACGOF ACMXC ACPOU ACPRK ACRPL ACSCC ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZMN AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFNX AFFPM AFGKR AFPWT AFRAH AFWVQ AFZJQ AHBTC AHMBA AI. AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EBD EBS ECGQY EJD ELTNK EMOBN F00 F01 F04 F5P FEDTE FUBAC G-S G.N GNP GODZA H.X HBH HF~ HGLYW HHY HHZ HVGLF HZ~ IX1 J0M JPC KBYEO KQQ L7B LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES M65 MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ NNB O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 QRW R.K RGB RIWAO RJQFR ROL RWI RX1 RYL SAMSI SUPJJ SV3 TEORI TUS UB1 V2E VH1 W8V W99 WBKPD WHG WIB WIH WIJ WIK WJL WNSPC WOHZO WQJ WRC WUP WXI WXSBR WYISQ X7M XG1 XPP XV2 ZGI ZXP ZZTAW ~IA ~KM ~WT AAYXX AEYWJ AGHNM AGQPQ AGYGG CITATION CGR CUY CVF ECM EIF NPM 7QL 7TK 7U9 8FD AAMMB AEFGJ AGXDD AIDQK AIDYY C1K FR3 H94 K9. M7N P64 RC3 7X8 5PM |
ID | FETCH-LOGICAL-c5375-d182d88ecb16565f553ffb1226850dc448f5cef7908c0811973a97a090e6dae53 |
IEDL.DBID | DR2 |
ISSN | 0146-6615 1096-9071 |
IngestDate | Thu Aug 21 18:40:34 EDT 2025 Fri Jul 11 11:40:28 EDT 2025 Sat Jul 26 02:18:38 EDT 2025 Thu Apr 03 06:57:11 EDT 2025 Thu Apr 24 23:13:19 EDT 2025 Tue Jul 01 02:24:47 EDT 2025 Wed Jan 22 16:29:58 EST 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Keywords | neutralizing activity COVID-19 diagnostic assays SARS-CoV-2 serology |
Language | English |
License | 2020 Wiley Periodicals LLC. This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c5375-d182d88ecb16565f553ffb1226850dc448f5cef7908c0811973a97a090e6dae53 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ORCID | 0000-0003-0185-3147 0000-0002-1822-9861 0000-0003-1976-5663 |
OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC7675753 |
PMID | 33064340 |
PQID | 2490128356 |
PQPubID | 105515 |
PageCount | 0 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_7675753 proquest_miscellaneous_2451859305 proquest_journals_2490128356 pubmed_primary_33064340 crossref_citationtrail_10_1002_jmv_26605 crossref_primary_10_1002_jmv_26605 wiley_primary_10_1002_jmv_26605_JMV26605 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | April 2021 |
PublicationDateYYYYMMDD | 2021-04-01 |
PublicationDate_xml | – month: 04 year: 2021 text: April 2021 |
PublicationDecade | 2020 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: London – name: Hoboken |
PublicationTitle | Journal of medical virology |
PublicationTitleAlternate | J Med Virol |
PublicationYear | 2021 |
Publisher | Wiley Subscription Services, Inc John Wiley and Sons Inc |
Publisher_xml | – name: Wiley Subscription Services, Inc – name: John Wiley and Sons Inc |
References | 1988; 44 2020; 6 2020; 58 1997; 16 2020; 5 2020; 323 2014 2020; 20 2020; 52 2020 2020; 7821 e_1_2_10_12_1 e_1_2_10_10_1 e_1_2_10_11_1 e_1_2_10_22_1 Tang MS (e_1_2_10_9_1) 2020; 323 e_1_2_10_20_1 Boukli N (e_1_2_10_16_1) 2020 Zhou X‐H (e_1_2_10_13_1) 2014 Focosi D (e_1_2_10_21_1) 2020; 7821 e_1_2_10_2_1 e_1_2_10_4_1 e_1_2_10_18_1 e_1_2_10_3_1 e_1_2_10_19_1 e_1_2_10_6_1 e_1_2_10_5_1 e_1_2_10_17_1 e_1_2_10_8_1 e_1_2_10_14_1 e_1_2_10_7_1 e_1_2_10_15_1 |
References_xml | – volume: 58 start-page: 514 year: 2020 article-title: Evaluation of nucleocapsid and spike protein‐based enzyme‐linked immunosorbent assays for detecting antibodies against SARS‐CoV‐2 publication-title: J Clin Microbiol – volume: 7821 start-page: 437 year: 2020 article-title: Viral infection neutralization tests: A focus on severe acute respiratory syndrome‐coronavirus‐2 with implications for convalescent plasma therapy publication-title: Rev Med Virol – start-page: 1 year: 2020 end-page: 8 article-title: High incidence of false positive results in patients with other acute infections, using the LIAISON® SARS‐CoV‐2 commercial chemiluminescent micro‐particle immunoassay for detection of IgG anti SARS‐CoV‐2 antibodies publication-title: J Clin Microbiol – volume: 52 start-page: 583 year: 2020 end-page: 589 article-title: SARS‐CoV‐2 vaccines: status report publication-title: Immunity – volume: 6 start-page: 38 year: 2020 end-page: 39 article-title: SARS‐CoV‐2 infection serology: a useful tool to overcome lockdown? publication-title: Cell Death Discov – volume: 323 start-page: 1582 year: 2020 article-title: Clinical performance of two SARS‐CoV‐2 serologic assays publication-title: Clin Chem – volume: 20 start-page: 565 year: 2020 end-page: 574 article-title: Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS‐CoV‐2: an observational cohort study publication-title: Lancet Infect Dis – year: 2020 article-title: Decline of SARS‐CoV‐2‐specific IgG, IgM and IgA in convalescent COVID‐19 patients within 100 days after hospital discharge publication-title: Sci China: Life Sci – year: 2020 – volume: 16 start-page: 2143 year: 1997 end-page: 2156 article-title: Smooth non‐parametric receiver operating characteristic (ROC) curves for continuous diagnostic tests publication-title: Stat Med – volume: 58 start-page: e01224 issue: 9 year: 2020 end-page: 20 article-title: Clinical and analytical performance of an automated serological test that identifies S1/S2 neutralizing IgG in covid‐19 patients semiquantitatively publication-title: J Clin Microbiol – volume: 44 start-page: 837 year: 1988 end-page: 845 article-title: Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach publication-title: Biometrics – year: 2014 – volume: 5 start-page: 43 year: 2020 article-title: Universal coronavirus vaccines: the time to start is now publication-title: NPJ Vaccines – volume: 7821 start-page: 437 year: 2020 ident: e_1_2_10_21_1 article-title: Viral infection neutralization tests: A focus on severe acute respiratory syndrome‐coronavirus‐2 with implications for convalescent plasma therapy publication-title: Rev Med Virol – ident: e_1_2_10_10_1 doi: 10.15557/PiMR.2020.0024 – ident: e_1_2_10_6_1 doi: 10.1101/2020.03.18.20038018 – ident: e_1_2_10_2_1 doi: 10.1038/s41420-020-0275-2 – ident: e_1_2_10_15_1 doi: 10.2307/2531595 – volume-title: Statistical Methods in Diagnostic Medicine year: 2014 ident: e_1_2_10_13_1 – start-page: 1 year: 2020 ident: e_1_2_10_16_1 article-title: High incidence of false positive results in patients with other acute infections, using the LIAISON® SARS‐CoV‐2 commercial chemiluminescent micro‐particle immunoassay for detection of IgG anti SARS‐CoV‐2 antibodies publication-title: J Clin Microbiol – ident: e_1_2_10_17_1 doi: 10.1101/2020.03.30.20047365 – ident: e_1_2_10_7_1 doi: 10.1101/2020.07.09.20148429 – ident: e_1_2_10_12_1 – ident: e_1_2_10_19_1 doi: 10.1016/j.immuni.2020.03.007 – ident: e_1_2_10_18_1 doi: 10.1038/s41541-020-0198-1 – ident: e_1_2_10_3_1 doi: 10.1128/JCM.00461-20 – ident: e_1_2_10_5_1 doi: 10.3389/fmolb.2020.00157 – ident: e_1_2_10_14_1 doi: 10.1002/(SICI)1097-0258(19971015)16:19<2143::AID-SIM655>3.0.CO;2-3 – ident: e_1_2_10_20_1 doi: 10.1101/2020.07.21.20159178 – volume: 323 start-page: 1582 year: 2020 ident: e_1_2_10_9_1 article-title: Clinical performance of two SARS‐CoV‐2 serologic assays publication-title: Clin Chem – ident: e_1_2_10_8_1 doi: 10.1007/s11427-020-1805-0 – ident: e_1_2_10_4_1 doi: 10.1016/S1473-3099(20)30196-1 – ident: e_1_2_10_22_1 doi: 10.1128/JCM.01224-20 – ident: e_1_2_10_11_1 |
SSID | ssj0008922 |
Score | 2.5128613 |
Snippet | Plenty of serologic tests for severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) have been developed so far, thus documenting the importance of... Plenty of serologic tests for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed so far, thus documenting the importance of... |
SourceID | pubmedcentral proquest pubmed crossref wiley |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 2160 |
SubjectTerms | Algorithms Animals Antibodies Antibodies, Neutralizing Antibodies, Viral - blood Chlorocebus aethiops Comparative analysis Coronaviridae Coronaviruses Correlation analysis COVID-19 COVID-19 - blood COVID-19 - epidemiology COVID-19 - immunology COVID-19 - virology COVID-19 Testing - methods COVID‐19 diagnostic assays Humans Immune response Immunoglobulin G Immunoglobulin G - blood Italy - epidemiology Laboratories Neutralizing neutralizing activity Pandemics SARS-CoV-2 - immunology SARS‐CoV‐2 serology Sensitivity and Specificity Serologic Tests - methods Serology Severe acute respiratory syndrome Severe acute respiratory syndrome coronavirus 2 Vaccines Vero Cells Viral diseases Virology |
Title | Weak correlation between antibody titers and neutralizing activity in sera from SARS‐CoV‐2 infected subjects |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fjmv.26605 https://www.ncbi.nlm.nih.gov/pubmed/33064340 https://www.proquest.com/docview/2490128356 https://www.proquest.com/docview/2451859305 https://pubmed.ncbi.nlm.nih.gov/PMC7675753 |
Volume | 93 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELaqHhAXaHkuFGQQBy7ZJnG8jtVTVVFVlZZDS0sPSJGf6lLIVs0GqT3xE_ob-SXM2EnKUpAQlyiRJy_b4_nGHn9DyBvlU-89kwmAZZMUNmUJoGqbCFMypwsmlMb5jun7yd5RsX_CT1bIVr8XJvJDDBNuqBlhvEYFV7rZvCEN_fz12xisS-AvxVgtBEQHN9RRpYwrCDASJGCDeM8qlOabw53LtugWwLwdJ_krfg0GaPc--dR_eow7ORu3Cz02V7-xOv7nv62Rex0wpduxJ62TFVc_IHem3dL7Q3L-0akzajCZRwyfo12IF4W2mem5vaSBormBa0tr14YplCuwjBT3TmCKCjqrKWadoLinhR5uHxz--H69Mz-GY05jVJiztGk1zg01j8jR7rsPO3tJl64hMZwJnlhwVWxZOqOR0Yd7zpn3OgN8V_LUGvADPTfOC5mWBoBIJgVTUqhUpm5ilePsMVmt57V7SmhRykJOPHOFlkWqhc4yX2Sl5l6oHKzpiLztG64yHZc5ptT4UkUW5ryCGqxCDY7I60H0PBJ4_Eloo2_9qtPhpgLHFK0345MReTUUg_bhkoqq3bxFGZ4hYxw-4knsLMNbGDp3rEhHRCx1o0EAmb2XS-rZaWD4RoYd8CPhN0Mv-fuHV_vT43Dy7N9Fn5O7OQbmhPCjDbK6uGjdC0BWC_0yqNBPVdwisA |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELaqIgGX8i5LWzCIA5dsnThexxKXqlAtpdtDX_SCotixxbaQrdhNJXriJ_Ab-SWdsZOUpSAhLlEiTxK_xvPw-BtCXhaOOee4ikBZNlFaMh6BVl1G0mTc6pTLQqO_Y7Q7GB6m28fieIG8bs_CBHyIzuGGnOHXa2RwdEivX6GGnnw574N4QQDTG5jRG9nyzd4VeFSmwh4CrAURSCHR4gqxZL17dV4aXVMxr0dK_qrBehG0dYd8bCsfIk9O-_VM983Fb7iO_9u6u2Sp0U3pRphM98iCre6Tm6Nm9_0BOftgi1NqMJ9HiKCjTZQXheEZ60n5jXqU5ik8l7SytfeiXIBwpHh8ArNU0HFFMfEExWMtdH9jb__n9x-bkyO4JjQEhtmSTmuN7qHpQ3K49fZgcxg1GRsiI7gUUQnWSpll1mgE9RFOCO6cjkHFywQrDZiCThjrpGKZAV0kVpIXShZMMTsoCyv4I7JYTSr7mNA0U6kaOG5TrVKmpY5jl8aZFk4WCQjUHnnVjlxuGjhzzKrxOQ9AzEkOPZj7HuyRFx3pWcDw-BPRajv8ecPG0xxsUxTgXAx65HlXDAyIuypFZSc10ogYQePwE8thtnR_4Wjf8ZT1iJybRx0BgnvPl1TjTx7kG0F2wJSEZvpp8veK59ujI3_z5N9Jn5Fbw4PRTr7zbvf9CrmdYJyOj0ZaJYuzr7VdA0Vrpp96froEUSUmyQ |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELaqIlVceEMXChjEgUu2TmznIU5Vy6oUtkItLT0gRfFLLIXsit0g0RM_gd_IL2HGTlKWgoS4RIk8Sfwaz8Pjbwh5UjnmnONFBMqyjoRhPAKt2kSZzrlVgmeVQn_HeD_dPRJ7J_JkhTzrzsIEfIje4Yac4ddrZPCZcZvnoKEfPn0ZgnRB_NJLImU5Wl47B-fYUXkRthBgKYhACMkOVoglm_2ry8LogoZ5MVDyVwXWS6DRVfKuq3sIPDkdNgs11Ge_wTr-Z-OukSutZkq3wlS6TlZsfYOsjdu995tk9tZWp1RjNo8QP0fbGC8KgzNRU_OVeozmOTwbWtvG-1DOQDRSPDyBOSropKaYdoLioRZ6uHVw-OPb9-3pMVwTGsLCrKHzRqFzaH6LHI2ev9nejdp8DZGWPJORAVvF5LnVCiF9pJOSO6diUPByyYwGQ9BJbV1WsFyDJhIXGa-KrGIFs6mprOS3yWo9re06oSIvRJE6boUqBFOZimMn4lxJl1UJiNMBedoNXKlbMHPMqfGxDDDMSQk9WPoeHJDHPeksIHj8iWijG_2yZeJ5CZYpim8u0wF51BcD--GeSlXbaYM0MkbIOPzEnTBZ-r9wtO64YAOSLU2jngChvZdL6sl7D_GNEDtgSEIz_Sz5e8XLvfGxv7n776QPydrrnVH56sX-y3vkcoJBOj4UaYOsLj439j5oWQv1wHPTT-tQJYE |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Weak+correlation+between+antibody+titers+and+neutralizing+activity+in+sera+from+SARS%E2%80%90CoV%E2%80%902+infected+subjects&rft.jtitle=Journal+of+medical+virology&rft.au=Criscuolo%2C+Elena&rft.au=Diotti%2C+Roberta+A.&rft.au=Strollo%2C+Marta&rft.au=Rolla%2C+Serena&rft.date=2021-04-01&rft.issn=0146-6615&rft.eissn=1096-9071&rft.volume=93&rft.issue=4&rft.spage=2160&rft.epage=2167&rft_id=info:doi/10.1002%2Fjmv.26605&rft.externalDBID=10.1002%252Fjmv.26605&rft.externalDocID=JMV26605 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0146-6615&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0146-6615&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0146-6615&client=summon |